Stallergenes forges $198M pact for allergy R&D

France's Stallergenes has inked a deal worth up to $198 million with biotech DBV Technologies, partnering with the company to develop a treatment for birch allergy. Under the agreement, DBV will apply its Viaskin drug delivery platform to one of Stallergenes' preclinical candidates, and the company is eligible for royalties if the resulting therapy hits the market. More